Absci's Proof-of-Concept Readout Could Redefine Its AI Drug Platform Narrative

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Absci reports before the market opens, meaning Day 0 captures the first full trading session where investors react to results, while Day +1 reflects follow-through momentum.

Absci has exhibited significant volatility around earnings, with an average absolute Day 0 move of 4.53% and Day +1 move of 6.58%. The Day 0 trading range averages 7.13%, while Day +1 expands to 16.48%, indicating that the stock often sees substantial intraday swings and continued volatility into the following session.

The most dramatic moves occurred in November 2024, when the stock dropped 14.95% on Day 0 and continued falling 13.74% on Day +1, reflecting a severe negative reaction. More recently, the August 2026 report saw a modest 4.44% gain on Day 0 with relatively contained volatility. The May 2026 report showed a 3.36% decline on Day 0 but then reversed with a 2.61% gain on Day +1, demonstrating the stock's tendency for sharp reversals.

Investors should expect meaningful price movement following this release, with historical patterns suggesting the stock could easily move 5-10% or more in either direction, particularly given the heightened focus on the upcoming December ABS-201 data readout.

Part 2.2: Options Market Expected Move

The options market is pricing in a 13.38% expected move for the November 20 expiration, which is notably higher than the historical average Day 0 move of 4.53% but more in line with the average Day +1 move of 6.58%. The options expected move appears to reflect elevated uncertainty, likely driven by investor anticipation of commentary around the upcoming December ABS-201 proof-of-concept data rather than the quarterly results themselves. Given the stock's history of volatile post-earnings swings—particularly the 16.48% average Day +1 range—the options market's pricing seems reasonable and suggests traders are bracing for significant movement.

Part 3: What Analysts Are Saying

Absci commands strong analyst support, with a consensus rating that translates to Strong Buy territory. The average price target of $14.82 implies substantial upside of approximately 46% from the current price of $10.12, with a high estimate of $20.00 and a low of $10.00.

The analyst breakdown shows 10 Strong Buy ratings, 1 Moderate Buy, and 2 Hold ratings, with zero sell recommendations. This represents an average recommendation score of 4.62 on a 5-point scale, reflecting overwhelmingly bullish sentiment. Notably, the number of Strong Buy ratings has increased from 9 to 10 over the past month, while the Hold count has remained steady at 2, indicating that sentiment has improved recently.

The strengthening conviction appears tied to positive interim Phase 1 data for ABS-201 and the strategic validation provided by Eli Lilly's $40 million investment. Recent upgrades include KeyBanc raising its target to $20 (the high estimate), JPMorgan lifting its target to $15, and Jefferies initiating coverage with a Buy rating and $14 target. The consensus view is that Absci's AI platform offers a differentiated approach to biologics discovery, with the upcoming December proof-of-concept data representing a critical inflection point that could validate the company's technology and justify the bullish price targets.

Part 4: Technical Picture

Absci's technical setup heading into earnings shows strengthening momentum. The Barchart Technical Opinion currently registers a 100% Buy signal, up from 100% Buy last week and 64% Buy a month ago, indicating sustained and improving bullish sentiment across technical indicators.

Timeframe Analysis:

• Short-term (100% Buy): Strong buy signal indicates near-term momentum is decisively positive, with the stock showing clear upward trajectory heading into the earnings release
• Medium-term (100% Buy): Continued strength in the intermediate timeframe suggests the uptrend is well-established and supported by broader technical factors
• Long-term (100% Buy): Maximum bullish reading in the longer-term trend confirms that the stock has built a solid foundation of support across all time horizons

Trend Characteristics: The technical environment is characterized by Good strength with a Strengthening direction, suggesting that momentum is not only positive but accelerating into the earnings event—a supportive backdrop for the release.

The stock is currently trading at $10.12, positioned above its 5-day ($10.09), 20-day ($9.95), 50-day ($9.65), 100-day ($9.46), and 200-day ($6.77) moving averages, though it sits slightly below the 10-day average of $10.39. This configuration indicates a strong uptrend across all major timeframes, with the stock having rallied sharply from its 200-day average.

The stock's position above all key long-term moving averages—particularly the 49% premium to its 200-day average—reflects substantial momentum that has built throughout 2026. The brief dip below the 10-day moving average appears to be minor consolidation rather than a trend reversal, as the stock remains well-supported by the 20-day and 50-day averages. The technical setup is decidedly supportive heading into earnings, with the 100% Buy signal across all timeframes suggesting that momentum traders are positioned bullishly. However, the elevated technical readings also mean the stock has less room for disappointment—any negative surprise or cautious commentary around the December ABS-201 data could trigger profit-taking given the strong year-to-date gains.